Anti-PD-1 mainly inhibits tumor proliferation by inducing tumor infiltration of CD8+ T cells, while anti-CTLA-4 plays an immunotherapy role by inducing CD8+ effector T cells and CD8+ T-cell proliferation. This evidence concerns the gene CD8A and neoplasm.